CASI
Price:
$0.9783
Market Cap:
$15.16M
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Pha...[Read more]
Industry
Biotechnology
IPO Date
1996-06-12
Stock Exchange
NASDAQ
Ticker
CASI
According to CASI Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.32. This represents a change of -48.70% compared to the average of -0.62 of the last 4 quarters.
The mean historical PE Ratio of CASI Pharmaceuticals, Inc. over the last ten years is -6.36. The current -0.32 PE Ratio has changed 403.22% with respect to the historical average. Over the past ten years (40 quarters), CASI's PE Ratio was at its highest in in the December 2022 quarter at -0.33. The PE Ratio was at its lowest in in the June 2018 quarter at -30.21.
Average
-6.36
Median
-5.43
Minimum
-18.56
Maximum
-0.60
Discovering the peaks and valleys of CASI Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 496.19%
Maximum Annual PE Ratio = -0.60
Minimum Annual Increase = -79.95%
Minimum Annual PE Ratio = -18.56
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -1.11 | -68.86% |
| 2023 | -3.55 | 496.19% |
| 2022 | -0.60 | -79.95% |
| 2021 | -2.97 | -55.98% |
| 2020 | -6.75 | 3.24% |
| 2019 | -6.54 | -47.30% |
| 2018 | -12.40 | -33.19% |
| 2017 | -18.56 | 173.12% |
| 2016 | -6.80 | 57.24% |
| 2015 | -4.32 | 197.78% |
The current PE Ratio of CASI Pharmaceuticals, Inc. (CASI) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.75
5-year avg
-2.99
10-year avg
-6.36
CASI Pharmaceuticals, Inc.’s PE Ratio is less than Clearside Biomedical, Inc. (-0.18), less than Cingulate Inc. (-0.00), less than Entero Therapeutics, Inc. (-0.25), greater than Curis, Inc. (-0.58), greater than Pelthos Therapeutics Inc. (-3.42), less than NuCana plc (-0.11), greater than Palisade Bio, Inc. (-1.20), greater than Allarity Therapeutics, Inc. (-1.12), greater than Kairos Pharma, Ltd. (-3.63), greater than Lisata Therapeutics, Inc. (-0.97),
| Company | PE Ratio | Market cap |
|---|---|---|
| -0.18 | $4.97M | |
| -0.00 | $22.09M | |
| -0.25 | $11.06M | |
| -0.58 | $17.45M | |
| -3.42 | $17.09M | |
| -0.11 | $26.90M | |
| -1.20 | $268.21M | |
| -1.12 | $16.85M | |
| -3.63 | $18.86M | |
| -0.97 | $17.90M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like CASI Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like CASI Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is CASI Pharmaceuticals, Inc.'s PE Ratio?
How is the PE Ratio calculated for CASI Pharmaceuticals, Inc. (CASI)?
What is the highest PE Ratio for CASI Pharmaceuticals, Inc. (CASI)?
What is the 3-year average PE Ratio for CASI Pharmaceuticals, Inc. (CASI)?
What is the 5-year average PE Ratio for CASI Pharmaceuticals, Inc. (CASI)?
How does the current PE Ratio for CASI Pharmaceuticals, Inc. (CASI) compare to its historical average?